Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial–mesenchymal transition

Ying BAO1*, Yibo ZHANG2*, Yongliang LU3*, Huihui GUO1*, Zhaohuo DONG1, Qiuqiang CHEN1, Xilin ZHANG1, Weiyun SHEN1, Wei CHEN4, Xiang WANG1

1Key Laboratory for Translational Medicine, First Affiliated Hospital, Huzhou University, the First People’s Hospital of Huzhou, huzhou 313000, China
2Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China
3Department of medicine, Huzhou University, huzhou 313000, China
4Institute of Molecular Engineering, University of Chicago, Chicago, 60637, USA.
* Contributed equally to this work

Address corresponding to:
Xiang WANG, First Affiliated Hospital, Huzhou University, the First People’s Hospital of Huzhou, huzhou 313000, China.
Tel: +86572-2023728; Fax: +86572-2023728.
E-mail address: wangx2017@126.com
Wei Chen, Institute of Molecular Engineering, University of Chicago, Chicago, 60637, USA
Tel: +1 8722128084; Fax+1 7737027752
E-mail address: weichen@uchicago.edu
Figure S1

a. Real-time PCR was determined to detect the level of miR-9 after EIF5A2 knockdown or not. b. Tumor weight of xenograft tumors treated with control, cisplatin, miR-9 mimic, or cisplatin plus miR-9 mimic (n = 4 per group). **P < 0.01, ***P < 0.001 vs Control.
Figure S2

a-b. CCK-8 determined the sensitivity to doxorubicin after transfected with miR-9 mimic, inhibitor, control or NC in HCC cells.
Figure S3
TUNEL of apoptosis in the treatment groups and Ki-67 staining in the treatment groups and rate of Ki-67 positive staining.